KPI data tables
Takeda operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Gastroenterology | Rare Diseases | Plasma-Derived Therapies | Oncology | Neuroscience | Vaccines | Other |
|---|---|---|---|---|---|---|---|
| FY26 Q2 | 390.7 | 189.7 | 277.2 | 151.4 | 107.3 | 22.7 | 48.1 |
| FY26 Q1 | 386.1 | 206 | 283.9 | 165.6 | 113.6 | 14 | 50.7 |
| FY25 Q4 | 328.8 | 188.2 | 267 | 143.5 | 99.8 | 4.6 | 62.6 |
| FY25 Q3 | 385.8 | 194 | 273.1 | 148.8 | 108.4 | 23.3 | 58.3 |
| FY25 Q2 | 353.5 | 184.1 | 256.6 | 149.1 | 97.5 | 20.2 | 51.9 |
| FY25 Q1 | 339.3 | 196.4 | 260.9 | 138.8 | 108.6 | 11.5 | 51.2 |
Source: Takeda Quarterly Financial Report for the quarter ended 30 June 2026, Product Sales Analysis (Reported AER and Core CER Change) business-area rows (billion JPY). FY25 Q1 through FY26 Q1: GI 339.3 / 353.5 / 385.8 / 328.8 / 386.1; Rare Diseases 196.4 / 184.1 / 194.0 / 188.2 / 206.0; PDT 260.9 / 256.6 / 273.1 / 267.0 / 283.9; Oncology 138.8 / 149.1 / 148.8 / 143.5 / 165.6; Neuroscience 108.6 / 97.5 / 108.4 / 99.8 / 113.6; Vaccines 11.5 / 20.2 / 23.3 / 4.6 / 14.0; Other 51.2 / 51.9 / 58.3 / 62.6 / 50.7. PDF: https://assets-dam.takeda.com/image/upload/v1785376662/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_qfr_en.pdf. Same Q1 FY2025 and Q1 FY2026 area totals in Form 6-K filed 30 July 2026, Exhibit 1 (English kessan tanshin) Revenue by Business Area: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm. FY26 Q2 (Jul-Sep): Takeda Quarterly Financial Report for the six months ended 30 September 2026, Product Sales Analysis (Reported AER and Core CER Change) Q2 column: GI 390.7; Rare Diseases 189.7; PDT 277.2; Oncology 151.4; Neuroscience 107.3; Vaccines 22.7; Other 48.1. PDF: https://assets-dam.takeda.com/image/upload/v1793241842/Global/Investor/Financial-Results/FY2026/Q2/qr2026_q2_qfr_en.pdf. Semi-annual Securities Report in Form 6-K filed 29 October 2026 (six-month totals, consistent): https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm. IR library: https://www.takeda.com/investors/financial-results/quarterly-results/
| Period | Gastroenterology | Rare Diseases | Plasma-Derived Therapies | Oncology | Neuroscience | Vaccines | Other |
|---|---|---|---|---|---|---|---|
| FY2025 | 1,407.5 | 762.7 | 1,057.5 | 580.1 | 414.3 | 59.6 | 224 |
| FY2024 | 1,357 | 752.8 | 1,032.7 | 560.4 | 565.8 | 55.4 | 257.4 |
| FY2023 | 1,216.2 | 688.4 | 903.7 | 462.4 | 627 | 50.4 | 315.7 |
Source: Takeda Form 20-F for the fiscal year ended 31 March 2026, Revenue by Business Area (billion JPY), filed 17 June 2026: FY2024 (year ended 31 March 2025) and FY2025 (year ended 31 March 2026) GI 1,357.0 / 1,407.5; Rare Diseases 752.8 / 762.7; PDT 1,032.7 / 1,057.5; Oncology 560.4 / 580.1; Vaccines 55.4 / 59.6; Neuroscience 565.8 / 414.3; Other 257.4 / 224.0. https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm. FY2023 (year ended 31 March 2024) from Form 6-K filed 8 May 2025, Exhibit 1 English kessan tanshin Revenue by Business Area: GI 1,216.2; Rare Diseases 688.4; PDT 903.7; Oncology 462.4; Vaccines 50.4; Neuroscience 627.0; Other 315.7. https://www.sec.gov/Archives/edgar/data/1395064/000139506425000048/form6k-1_050825.htm. Revised FY2025 year-end Quarterly Financial Report (5 June 2026) reprints the FY2025 area totals: https://assets-dam.takeda.com/image/upload/v1780626052/Global/Investor/Financial-Results/FY2025/Q4_0605/qr2025_q4_qfr_en_20260605.pdf.
| Period | ENTYVIO sales |
|---|---|
| FY26 Q2 | 273.4 |
| FY26 Q1 | 268.3 |
| FY25 Q4 | 213.5 |
| FY25 Q3 | 265.3 |
| FY25 Q2 | 246.7 |
| FY25 Q1 | 232.5 |
| FY24 Q4 | 215.1 |
| FY24 Q3 | 225.8 |
| FY24 Q2 | 238.9 |
| FY24 Q1 | 234.4 |
| FY23 Q4 | 181.6 |
| FY23 Q3 | 227.6 |
| FY23 Q2 | 199.7 |
| FY23 Q1 | 192 |
| FY22 Q4 | 154.9 |
| FY22 Q3 | 201.3 |
| FY22 Q2 | 178.3 |
| FY22 Q1 | 168.3 |
| FY21 Q4 | 126.4 |
| FY21 Q3 | 139.5 |
| FY21 Q2 | 130.5 |
| FY21 Q1 | 125.4 |
| FY20 Q4 | 110 |
| FY20 Q3 | 112.3 |
Source: Takeda Form 6-K English kessan tanshin (CIK 0001395064) Q1 three-month ENTYVIO print in JPY billions; Q2–Q4 tanshin ENTYVIO figures are YTD and were not assigned. Quarterly FLOW from QFR Product Sales Analysis (Reported AER & Core CER Change) sheet, billion JPY, not U.S./Europe split, not CER %. Later package wins. FY24 Q1 234.4 https://www.sec.gov/Archives/edgar/data/1395064/000139506424000153/form6k_073124.htm FY25 Q1 232.5 https://www.sec.gov/Archives/edgar/data/1395064/000139506425000120/form-6k_073025.htm FY26 Q1 268.3 https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm FY26 Q2 273.4 (QFR Product Sales Analysis Q2 quarterly column; the Form 6-K of 29 October 2026 prints only the six-month 541.7, which equals 268.3 plus 273.4 within rounding) https://assets-dam.takeda.com/image/upload/v1793241842/Global/Investor/Financial-Results/FY2026/Q2/qr2026_q2_qfr_en.pdf https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm QFR Excel: https://assets-dam.takeda.com/raw/upload/v1746751088/Global/Investor/Financial-Results/FY2024/Q4/qr2024_q4_ex_en.xlsx https://assets-dam.takeda.com/raw/upload/v1753840015/Global/Investor/Financial-Results/FY2025/Q1/qr2025_q1_ex_en.xlsx https://assets-dam.takeda.com/raw/upload/v1768284308/Global/Investor/Financial-Results/FY2025/Q2/qr2025_q2_ex_en.xlsx https://assets-dam.takeda.com/raw/upload/v1769652745/Global/Investor/Financial-Results/FY2025/Q3/qr2025_q3_ex_en.xlsx https://assets-dam.takeda.com/raw/upload/v1780626006/Global/Investor/Financial-Results/FY2025/Q4_0605/qr2025_q4_ex_en_20260605.xlsx https://assets-dam.takeda.com/raw/upload/v1785376898/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_ex_en.xlsx
| Period | Immunoglobulin | Albumin |
|---|---|---|
| FY26 Q2 | 209.9 | 34.5 |
| FY26 Q1 | 213.9 | 34.6 |
| FY25 Q4 | 196.9 | 38.7 |
| FY25 Q3 | 206.6 | 35.5 |
| FY25 Q2 | 193 | 33.9 |
| FY25 Q1 | 194 | 32.2 |
Source: Takeda Quarterly Financial Report for the quarter ended 30 June 2026, Product Sales Analysis Immunoglobulin and Albumin rows (billion JPY). Immunoglobulin FY25 Q1 194.0, Q2 193.0, Q3 206.6, Q4 196.9, FY26 Q1 213.9 (plus 10.2% AER, minus 0.6% CER). Albumin FY25 Q1 32.2, Q2 33.9, Q3 35.5, Q4 38.7, FY26 Q1 34.6 (plus 7.5% AER, minus 5.0% CER). Four FY2025 IG quarters sum to 790.5 versus the printed annual 790.6. PDF: https://assets-dam.takeda.com/image/upload/v1785376662/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_qfr_en.pdf. Form 6-K filed 30 July 2026, Exhibit 1 PDT narrative: immunoglobulin 213.9, albumin 34.6, PDT 283.9. https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm. FY2026 Q1 earnings presentation PDT slides (SCIG plus 17% CER; IG 213.9; albumin 34.6): https://assets-dam.takeda.com/image/upload/v1785376796/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_p01_en.pdf. FY26 Q2 immunoglobulin 209.9 (plus 8.7% AER, plus 0.1% CER), albumin 34.5 (plus 1.7% AER, minus 8.7% CER): Takeda Quarterly Financial Report for the six months ended 30 September 2026, Product Sales Analysis Q2 column: https://assets-dam.takeda.com/image/upload/v1793241842/Global/Investor/Financial-Results/FY2026/Q2/qr2026_q2_qfr_en.pdf. Form 6-K filed 29 October 2026 (Semi-annual Securities Report) prints six-month immunoglobulin 423.8 and albumin 69.1, equal to the Q1 plus Q2 values within rounding: https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm.
| Period | Japan | United States | Europe and Canada | Latin America | China | Rest of world |
|---|---|---|---|---|---|---|
| FY2025 | 433.1 | 2,164.8 | 1,146.2 | 254.1 | 195.1 | 312.3 |
| FY2024 | 418.5 | 2,379.7 | 1,055.3 | 235.8 | 191.7 | 300.6 |
| FY2023 | 451.4 | 2,195.7 | 966.8 | 198.1 | 174.8 | 276.9 |
Source: Takeda Form 20-F for the fiscal year ended 31 March 2026, Revenue by Geographic Region (billion JPY), filed 17 June 2026. FY2024 / FY2025: Japan 418.5 / 433.1; United States 2,379.7 / 2,164.8; Europe and Canada 1,055.3 / 1,146.2; Latin America 235.8 / 254.1; China 191.7 / 195.1; Asia excluding Japan and China 99.4 / 98.7; Russia/CIS 72.4 / 79.7; Other 128.8 / 133.9. https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm. FY2023 (year ended 31 March 2024) from the same 20-F prior-year comparison block and from Form 6-K filed 8 May 2025 Exhibit 1: Japan 451.4; United States 2,195.7; Europe and Canada 966.8; Latin America 198.1; China 174.8; Asia excluding Japan and China 86.4; Russia/CIS 72.6; Other 117.9. https://www.sec.gov/Archives/edgar/data/1395064/000139506425000048/form6k-1_050825.htm. FY26 Q1 reclassification note (Canada moved to Other) is in the Q1 FY2026 Quarterly Financial Report and is not applied to this annual series: https://assets-dam.takeda.com/image/upload/v1785376662/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_qfr_en.pdf.